IHAM
HALO icon

Integral Health Asset Management’s Halozyme HALO Stock Holding History

Integral Health Asset Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-155,000
Closed -$4.07M – 72
2020
Q3 		$4.07M Buy
155,000
+20,000
+15% +$557K 1.25% 29
2020
Q2 		$3.62M Buy
135,000
+85,000
+170% +$1.92M 1.08% 37
2020
Q1 		$900K Buy
+50,000
New +$949K 0.4% 49

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Integral Health Asset Management's HALO Position: Q4 2020 in Review

Integral Health Asset Management sold out of Halozyme (HALO) in Q4 2020, closing a stake of 155,000 shares — an estimated $4.07M sold.

Integral Health Asset Management first reported a position in HALO in Q1 2020 and held it in 3 quarters. The position peaked at $4.07M in Q3 2020. 342 funds tracked by Wall St. Rank hold HALO as of Q4 2020.

  • Integral Health Asset Management reported no remaining Halozyme position as of Q4 2020 after selling out during the quarter.
  • Integral Health Asset Management sold 155,000 Halozyme shares in Q4 2020, an estimated $4.07M.
  • Integral Health Asset Management first reported a position in Halozyme in Q1 2020 and held it in 3 quarters.
  • Integral Health Asset Management's Halozyme position peaked at $4.07M in Q3 2020.
  • 342 funds tracked by Wall St. Rank held Halozyme as of Q4 2020.

Based on Integral Health Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.